Showing 2851-2860 of 5685 results for "".
- Study: Ocular Technology Provides Early Detection of Alzheimer’s Diseasehttps://modernod.com/news/study-ocular-technology-provides-early-detection-of-alzheimers-disease/2479626/A recent study from JAMA Ophthalmology finds that a specific type of noninvasive eye testing procedure may help assess risk for Alzheimer’s disease. One in 10 Americans over the age 65 has Alzheimer’s, while one-third over the age of 85 have the disease. Fortunately, res
- Alcon’s Phaco Development (PD) Program Celebrates 10 Yearshttps://modernod.com/news/alcons-phaco-development-pd-program-celebrates-10-years/2476164/The Phaco Development (PD) program, an initiative between Alcon and specialist training institutes that builds cataract surgical capabilities across Asia and Russia, is celebrating its 10th anniversary this year. Over th
- Bausch + Lomb Announces Exclusive Agreement with Modulight to Develop New Photodynamic Laserhttps://modernod.com/news/bausch-lomb-announces-exclusive-agreement-with-modulight-to-develop-new-photodynamic-laser/2476166/Bausch + Lomb and Modulight, a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s Visudyne (verteporfin for injection)
- Ocular Therapeutix Announces FDA Approval of Dextenza for the Treatment of Ocular Pain Following Ophthalmic Surgeryhttps://modernod.com/news/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery/2476171/Ocular Therapeutix announced that the FDA has approved Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-
- Lynx Inventory System Now Customized for Retina Specialistshttps://modernod.com/news/lynx-inventory-system-now-customized-for-retina-specialists/2479638/McKesson announced that Lynx, its customizable, cloud-based medication inventory management system for specialty medical practices, has new features designed especially for delivering injectable medication therapies in retina practices. These customizations for retina specialists ensure that each
- FDA Revamping Clearance Procedures for Medical Deviceshttps://modernod.com/news/fda-revamping-clearance-procedures-for-medical-devices/2479649/The FDA is significantly revamping the way it clears most medical devices for U.S. marketing, planning to rely far less on comparisons with much older products already on the market, according to a
- Warby Parker Eyewear Now Available to People Enrolled in UnitedHealthcare Medicare Advantage Planshttps://modernod.com/news/warby-parker-eyewear-now-available-to-people-enrolled-in-unitedhealthcare-medicare-advantage-plans/2479652/For the first time, Warby Parker is accepting Medicare insurance. The company’s designer prescription eyewear is available to approximately 2 million people enrolled in UnitedHealthcare Medicare Advantage plans, either online or at more than 80 Warby Parker stores nationwide, according to a
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- Santen Expands Research and Development Leadership Teamhttps://modernod.com/news/santen-expands-research-and-development-leadership-team/2479666/Santen announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA
- Prevent Blindness Opens Nominations for 2019 Jenny Pomeroy Award for Excellence in Vision and Public Healthhttps://modernod.com/news/prevent-blindness-opens-nominations-for-2019-jenny-pomeroy-award-for-excellence-in-vision-and-public-health/2479669/Prevent Blindness is issuing a call for nominations for the 2019 Jenny Pomeroy Award for Excellence in Vision and Public Health. The award recognizes an individual, team, or organization that has made an outstanding contribution to the field of public health, and vision and eye health at a commun